Pluristem Therapeutics Inc PSTI
We take great care to ensure that the data presented and summarized in this overview for PLURISTEM THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PSTI
Top Purchases
Top Sells
About PSTI
Insider Transactions at PSTI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Lorne Kenneth Abony Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,750
+50.0%
|
-
|
|
Jan 23
2024
|
Rami Avraham Levi Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,100
+39.38%
|
-
|
|
Jan 23
2024
|
Yaky Yanay Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
700,000
+22.15%
|
-
|
|
Jan 23
2024
|
Maital Shemesh Rasmussen Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,150
+39.62%
|
-
|
|
Jan 23
2024
|
Pinhas Doron Birger Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,900
+39.98%
|
-
|
|
Jan 23
2024
|
Zami Aberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,100
+2.79%
|
-
|
|
Jan 23
2024
|
Chen Franco Yehuda Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
355,000
+42.89%
|
-
|
|
Dec 22
2022
|
Yaky Yanay Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
334,821
+15.98%
|
-
|
|
Dec 20
2022
|
Zami Aberman Director |
SELL
Open market or private sale
|
Direct |
2,000
-0.13%
|
$0
$0.97 P/Share
|
|
Feb 10
2022
|
Zami Aberman Director |
BUY
Open market or private purchase
|
Indirect |
80,616
+46.77%
|
$80,616
$1.8 P/Share
|
|
Jul 15
2021
|
Pinhas Doron Birger Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Jul 15
2021
|
Varda Shalev Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
May 28
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
115,007
-1.79%
|
$345,021
$3.72 P/Share
|
|
May 27
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
95,885
-1.45%
|
$287,655
$3.69 P/Share
|
|
May 26
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
144,678
-2.09%
|
$434,034
$3.69 P/Share
|
|
May 25
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
261,238
-6.99%
|
$783,714
$3.84 P/Share
|
|
May 24
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
79,300
-2.08%
|
$237,900
$3.83 P/Share
|
|
May 21
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
69,838
-1.8%
|
$209,514
$3.98 P/Share
|
|
May 03
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
23,721
-0.61%
|
$94,884
$4.28 P/Share
|
|
Apr 30
2021
|
Clover Wolf Capital Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
166,004
-4.07%
|
$664,016
$4.66 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.25M
Shares
From
7
Insiders
| Grant, award, or other acquisition | 1.25M shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders